Advances in Cancer Immunotherapy

ACI_10thLogo_500px.png

Advances in Cancer Immunotherapy™ (ACI) Series

ACI programs are certified for CME, CNE, CPE, and MOC credits. ACI's offer in-depth clinical training in immunotherapy treatment for a variety of disease states and topics for health professionals who wish to learn the most up-to-date clinical data for these treatments in order to inform and integrate them into their own clinical practice.

The 2024 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from Bristol Myers Squibb, and Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD). (Supporters as of Jan. 26, 2024)

2024 ACI Series

Featured Courses

Access interactive courses to supplement your knowledge! The online courses listed below are CME-, CPE-, CNE- and MOC-certified supplemental program courses for the ACI education series. Participation by clinicians is strongly recommended, however the courses are available to anyone.

Registration Information

Members of the Society for Immunotherapy of Cancer (SITC) are eligible for discounted registration rates. To receive discounted member rates, your membership dues must be current. Renew your dues or apply for membership. Please note your registration classification to determine the correct registration rate. For non-members, your classification is determined by your primary institution.

Register Now

Registration Rates

Rates per Program

SITC Member Rates Non-Member Rates
Student/Non-industry Nurse, Pharmacist or AP/Allied Health/Patient or Caregiver/Advocate/Foundation or Non-Profit $15 $25
Clinician/Academic $35 $50
Government $35 $50
Industry and Investor $600 $740
Low to Lower-Middle Income Economies (LMIE) $0 $25

Cancellation / Refund Policy

All cancellations must be received in writing. You may fax your cancellation to +1 414-276-3349 or e-mail events@sitcancer.org. Requests must be made 3 weeks prior to the event. A $25 processing fee will be charged for all paid registration cancellations.

All refunds will be processed after the programs; you will receive an e-mail confirmation. No refunds will be granted if cancellation is received after the 3 weeks out date. Special considerations will be given for health or family emergencies if requested in writing to events@sitcancer.org no later than 14 business days after the last day of the programs.

Photography Policy and Meeting Code of Conduct

SITC often employs the services of a professional photographer/videographer at SITC events to capture images and audiovisual (AV) recordings for use in society archival and promotional material. Your attendance at SITC events implies your permission for images and an AV recording captured to be used for purposes of SITC archival materials, promotional materials, and publications, and waives your rights for compensation or ownership of these images.

View the SITC Meeting Code of Conduct.

ACI Online Programming

SITC is pleased to offer free online, introductory, CME-, CPE-, CNE- and/or MOC-certified programs via the society's online learning portal, SITC Cancer Immunotherapy connectED. These online activities provide an overview of basic immunology principles and the mechanisms and clinical applications of immunotherapy. If you missed the opportunity to attend an Advances in Cancer Immunotherapy™ event, you can still obtain the education and CME, CPE, CNE and/or MOC credits through many of the online programs listed here.

View Online Programming

Learn more about online ACI courses

Complete these certified, interactive online courses to deepen your understanding of cancer immunotherapy and learn about the most recent FDA approvals in several diseases states and the latest guidelines on how to treat immune-related adverse events. Additional courses address how to overcome practical barriers to implementation, which are critical for helping your staff to help patients obtain reimbursement for immunotherapy. Each course is eligible for CME, CNE, CPE and/or MOC credits.

Online courses include links to the original trials, the latest FDA approvals, real-world case studies and questions to help deepen understanding and retention. There are also printable charts outlining best practices for treating immune-related adverse effects and links to the Cancer Immunotherapy Guidelines which can support decision-making.

Credit Information

Important to note, if you received credit for attending a live ACI, you cannot receive credit for the same online ACI course (e.g. you attended the ACI: A Focus on Lung Cancer live webinar, you could not also receive credit for the on-demand ACI: A Focus on Lung Cancer).

Click on each activity title to view full accreditation information and the types of credits offered for each program. 

2023 Enduring Materials

Missed a meeting? Materials are available for purchase for 2 weeks after the program date. Program materials for the Advances in Cancer ImmunotherapyTM programs prior to 2022 are available in the SITC Resource Library below. 

Purchase Enduring Materials Access

Please note, if you registered for an ACI meeting, you already have access to the enduring materials for that meeting and should not purchase. Please reach out to education@sitcancer.org with any questions.

Pricing for Enduring Materials

SITC Member Rates

Non-Member Rates

*Student, Patient, Caregiver

Free

Free

Non-Industry Nurse or Pharmacist, Patient Advocate, Foundation/Non-Profit, Patient Advocacy Organization

Free

Free

Clinician, Academic

Free

Free

Government, Non-Industry

Free

Free

Industry (Includes Industry Nurses & Pharmacists) and Investor

$150.00

$185.00

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC), the Advances in Cancer Immunotherapy™ (ACI) programs are CME-, CNE-, CPE- and MOC-certified programs, presented by leading authorities in tumor immunology and cancer immunotherapy. Each program will present the latest updates in the specific field addressed by the program, giving a deep dive into practical application, immune-related adverse events, and future trends.

Program Highlights

  • Overview of common approaches to cancer immunotherapy and their related mechanisms
  • Timely updates on the latest clinical advances in the field, including data from recent scientific meetings and clinical trials
  • Dedicated opportunities for clinicians to ask questions and receive direction on difficult cases
  • Strategies for addressing the practical barriers to implementing immunotherapy (operations, reimbursement and management of emerging toxicities)

Intended Audience

The ACI programs aim to reach practicing clinical oncologists, advanced practitioners, nurses, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

ACI Partners

SITC has partnered with the Association of Community Cancer Centers (ACCC) and the Advanced Practitioner Society for Hematology and Oncology (APSHO) to provide a comprehensive program providing critical information to incorporate immunotherapy into clinical practice.

ACI Committee

The Society for Immunotherapy of Cancer (SITC) is extremely grateful for the support of the following members of the Planning Committee for the Advances in Cancer Immunotherapy™ educational series.

2024 ACI Committee

  • Christian Capitini, MD
    University of Wisconsin Carbone Cancer Center
  • Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP (Chair)
    Smilow Cancer Hospital at Yale
  • Adi Diab, MD
    The University of Texas MD Anderson Cancer Center
  • Isabella C. Glitza, MD, PhD
    The University of Texas MD Anderson Cancer Center
  • Lisa A. Kottschade, APRN, MSN, CNP
    Mayo Clinic
  • Pradnya D. Patil, MD, FACP
    Dyson Cancer Center
  • Chrystal M. Paulos, PhD
    Winship Cancer Institute at Emory University
  • Mark P. Rubinstein, PhD
    The Ohio State University
  • Raju K. Vaddepally, MD
    Yuma Regional Medical Center Cancer Center
  • Dan P. Zandberg, MD
    UPMC Hillman Cancer Center
  • Lei Zheng, MD, PhD
    Johns Hopkins University School of Medicine

2023 ACI Committee

  • Sanjiv S. Agarwala, MD
    Temple University
  • Christian Capitini, MD (Chair)
    University of Wisconsin Carbone Cancer Center
  • Amber Cipriani, PharmD, BCOP, CPP
    UNC Healthcare
  • Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP (Co-chair
    Yale School of Nursing
  • Adi Diab, MD
    The University of Texas MD Anderson Cancer Center
  • Isabella C. Glitza, MD, PhD
    The University of Texas MD Anderson Cancer Center
  • Paul S. Jansson, MD, MS
    Harvard Medical School
  • Lisa Kottschade, APRN, MSN, CNP
    Mayo Clinic
  • Zihai Li, MD, PhD
    The Ohio State University
  • Pradnya Patil, MD, FACP
    Cleveland Clinic Taussig Cancer Center
  • Chrystal Paulos, PhD
    Emory University
  • Mark Rubinstein, PhD
    Cleveland Clinic Taussig Cancer Center
  • Raju Vaddepally, MD
    Yuma Regional Medical Center Cancer Center
  • Yiping Yang, MD, PhD
    The Ohio State University
  • Dan P. Zandberg, MD
    UPMC Hillman Cancer Center
  • Lei Zheng, MD, PhD
    Johns Hopkins University School of Medicine

2021-2022 ACI Committee

  • Sanjiv S. Agarwala, MD (Chair)
    Temple University
  • Christian Capitini, MD (Co-chair)
    University of Wisconsin Carbone Cancer Center
  • Amber Cipriani, PharmD, BCOP, CPP
    UNC Healthcare
  • Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
    Yale School of Nursing
  • Adi Diab, MD
    The University of Texas MD Anderson Cancer Center
  • Sarah B. Dubbs, MD, FAAEM
    University of Maryland School of Medicine
  • Isabella C. Glitza, MD, PhD
    The University of Texas MD Anderson Cancer Center
  • Zihai Li, MD, PhD
    The Ohio State University
  • Pradnya Patil, MD, FACP
    Cleveland Clinic Taussig Cancer Center
  • Chrystal Paulos, PhD
    Emory University
  • Mark Rubinstein, PhD
    Cleveland Clinic Taussig Cancer Center
  • Yiping Yang, MD, PhD
    The Ohio State University
  • Dan P. Zandberg, MD
    UPMC Hillman Cancer Center
  • Lei Zheng, MD, PhD
    Johns Hopkins University School of Medicine

Technology Policy and Information

For optimal completion of this program, the attendee will need a computer/laptop with a strong WiFi connection and the ability to stream video.

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

View the SITC Meeting Code of Conduct.